Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn
(NASDAQ: XAIR) Delayed: 3.09 +0.01 (0.32%)
Previous Close $3.08    52 Week High $ 
Open $3.07    52 Week Low $ 
Day High $3.26    P/E N/A 
Day Low $3.07    EPS $ 
Volume 38,844